Featured
Gate2Brain receives EMA Orphan Drug Designation for pioneering treatment of paediatric brain tumours
The European Medicines Agency (EMA) has awarded Orphan Drug Designation (ODD) to G2B-002, an innovative therapeutic candidate for the treatment of aggressive paediatric brain tumours, including diffuse intrinsic pontine glioma (DIPG) and paediatric glioblastoma (pGBM), developeb by gate2Brain, a spin-off from the Sant Joan de Déu Barcelona Children's Hospital.